Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BNTC 
Benitec Biopharma Ltd ADR (BNTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: BNTC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25.71
1 Year Target Price $25.71
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.31% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 308.44M USD | Price to earnings Ratio - | 1Y Target Price 25.71 |
Price to earnings Ratio - | 1Y Target Price 25.71 | ||
Volume (30-day avg) 7 | Beta 0.44 | 52 Weeks Range 7.05 - 17.15 | Updated Date 07/17/2025 |
52 Weeks Range 7.05 - 17.15 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.03 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.34% | Return on Equity (TTM) -48.57% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 245194714 | Price to Sales(TTM) 2770.13 |
Enterprise Value 245194714 | Price to Sales(TTM) 2770.13 | ||
Enterprise Value to Revenue 10457.68 | Enterprise Value to EBITDA 0.27 | Shares Outstanding 26250500 | Shares Floating 12567143 |
Shares Outstanding 26250500 | Shares Floating 12567143 | ||
Percent Insiders 3.12 | Percent Institutions 85.16 |
Upturn AI SWOT
Benitec Biopharma Ltd ADR
Company Overview
History and Background
Benitec Biopharma Ltd, established in 1997, is a biotechnology company focused on developing novel genetic medicines using its proprietary DNA-directed RNA interference (ddRNAi) platform technology. It has gone through multiple phases, including restructuring and focusing on specific therapeutic areas.
Core Business Areas
- Oncology: Benitec is focused on developing ddRNAi-based therapeutics for oncology, targeting specific genes involved in cancer development and progression.
- Ophthalmology: Benitec explores ddRNAi applications for ophthalmological disorders, aiming to address diseases affecting vision.
Leadership and Structure
Benitec Biopharma Ltd. is led by a management team with experience in biotechnology and drug development. The organizational structure includes departments for research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- BB-301: BB-301 is Benitec's leading clinical program, targeting Oculopharyngeal Muscular Dystrophy (OPMD). There is no current market share as the product is still in development. Competitors include companies developing gene therapies for muscular dystrophies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. Gene therapy is a growing field with significant potential.
Positioning
Benitec is a smaller player in the gene therapy space, focusing on ddRNAi technology. Its competitive advantage lies in the potential of its platform to offer targeted gene silencing.
Total Addressable Market (TAM)
The TAM for gene therapies addressing specific genetic disorders can be substantial, potentially reaching billions of dollars. Benitec's positioning depends on the successful clinical development and commercialization of its lead programs.
Upturn SWOT Analysis
Strengths
- Proprietary ddRNAi technology
- Focus on specific disease areas
- Experienced management team
Weaknesses
- Limited financial resources
- Reliance on single platform technology
- Early stage clinical development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
Threats
- Competition from established gene therapy companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- NTLA
- SRPT
Competitive Landscape
Benitec faces competition from larger, more established gene therapy companies. Its success depends on differentiating its ddRNAi platform and achieving positive clinical outcomes.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to its developmental stage. Future growth depends on clinical trial success.
Future Projections: Future projections are highly dependent on successful clinical outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical programs and exploring potential partnerships.
Summary
Benitec Biopharma is a high-risk, high-reward biotechnology company. Its ddRNAi technology has potential, but it faces challenges with clinical development, funding, and competition. Success hinges on its ability to execute its clinical programs and potentially partner with larger pharmaceutical companies. Its current financial structure means there is a risk of delisting due to the stock price.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Benitec Biopharma Ltd ADR
Exchange NASDAQ | Headquaters Hayward, CA, United States | ||
IPO Launch date 2015-08-18 | Executive Chairman & CEO Dr. Jerel A. Banks M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://benitec.com |
Full time employees 16 | Website https://benitec.com | ||
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.